Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modest improvement of metabolic and behavioral deficits with long-term ambroxol treatment in a Pink1-/-SNCAA53T double mutant mouse model of Parkinson's disease.

Acta pharmacologica Sinica - 1 Apr 2026

Franck Luisa, Valek Lucie, Hahnefeld Lisa, Trautmann Sandra, Angioni Carlo, Weyer Marc-Philipp, Thomas Dominique, Gurke Robert, Wittig Ilka, Geisslinger Gerd, Tegeder Irmgard

Abstract excerpt

Parkinson's disease (PD) involves α-synuclein (αSyn) oligomerization and aggregation, processes facilitated by glycosphingolipids. Defective glycosphingolipid transport and degradation-especially via the lipid-degrading enzyme glucocerebrosidase 1 (GCase, gene GBA1)-aggravate PD and increase dementia risk. Ambroxol is a mucolytic drug and has emerged as a promising add-on therapy for PD since it acts as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Synuclein
Share to Behavior, Animal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Models, Animal

Share to Glucosylceramidase

Share to Mice, Inbred C57BL

Share to Parkinson Disease

Share to Protein Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 41361659
DOI: 10.1038/s41401-025-01690-9
PMCID: PMC13018195

Genes

GBA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modest improvement of metabolic and behavioral deficits with long-term ambroxol treatment in a Pink1-/-SNCAA53T double mutant mouse model of Parkinson's disease.PMID 41361659Read ↗

Glucocerebrosidase mutations and Parkinson disease.Semantic proximity Read ↗

Hexosylceramides are elevated in human, mouse and cellular Parkinson's disease and cause gene upregulations in neurons mimicking responses to pathogensSemantic proximity Read ↗

Long-term oral regimen of glucocerebrosidase activator reduces a-synuclein oligomer accumulation in aged LRRK2 mutant mouse brains - therapeutic implication of Parkinson’s diseaseSemantic proximity Read ↗

Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments.Semantic proximity Read ↗

Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.Semantic proximity Read ↗

Glucocerebrosidase Mutations in Parkinson Disease.Semantic proximity Read ↗

Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications.Semantic proximity Read ↗

The interplay between Glucocerebrosidase, α-synuclein and lipids in human models of Parkinson’s diseaseSemantic proximity Read ↗

Neuronopathic GBA1 L444P mutation accelerates Glucosylsphingosine levels and formation of hippocampal alpha-synuclein inclusionsSemantic proximity Read ↗

An <i>N</i> -acylphosphatidylethanolamine-LRRK2 axis controls lysosomal homeostasis in Parkinson’s diseaseSemantic proximity Read ↗

Lysosomal Pathogenesis of Parkinson's Disease: Insights From LRRK2 and GBA1 Rodent Models.Semantic proximity Read ↗

Prodromal sensory neuropathy in Pink1-/- SNCAA53T double mutant Parkinson mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.